Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)
3189 Airway Avenue, Building C
267 articles with Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)
Tenax Therapeutics Announces New Clinical Study Publication Results Indicate Levosimendan Offers Renal Protective Benefits to Heart Failure Patients
Tenax Therapeutics , Inc. (NASDAQ: TENX) today announced the results of a new study titled "Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment: A Randomized Double‐Blind Controlled Trial” were published in the August 21, 2018 issue of the Journal of the American Heart Association (
Tenax Therapeutics, Inc. today announced the Company has selected board member Anthony A. DiTonno to be its next Chief Executive Officer, effective June 1, 2018.
Phase 2 clinical trial in the use of levosimendan for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction
Tenax Therapeutics Announces Results of Pre-IND Meeting with FDA for Phase 2 Study of Levosimendan in PH-HFpEF Patients
FDA addressed the Company’s questions and provided guidance on its upcoming Phase 2 clinical trial in the use of levosimendan for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction
Tenax has regained compliance with the Bid Price Rule and the matter is now closed.
Tenax Therapeutics Announces New Scientific Publication of Preclinical Data Provides Additional Evidence of Levosimendan Treatment Effects in Pulmonary Hypertension
Preclinical studies find levosimendan improves right heart function; Beneficial treatment for right heart failure secondary to pulmonary hypertension
World-Recognized Experts Join Tenax Therapeutics’ Scientific Advisory Board to Guide New Phase II Study
Tenax Therapeutics announced the appointment of three internationally recognized medical experts in the fields of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) to its Scientific Advisory Board for the company’s planned Phase 2 clinical study in the use of levosimendan for patients with PH-HFpEF.
Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies
Tenax announced plans to advance the development of levosimendan for the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF).
Tenax Therapeutics Meets With FDA To Discuss Positive Mortality Data And Potential Levosimendan NDA Submission
Tenax Therapeutics Announces Completion Of Enrollment For Phase III LEVO-CTS Trial In Cardiac Surgery